Ho Sup Lee |
6 Articles |
|
Hemato-oncology
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee; Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Korean J Intern Med. 2023;38(5):734-746. Published online June 20, 2023
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).
Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in ..
|
|
|
Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
Seom Gim Kong, Je-Hwan Lee, Young Tak Lim, Ji Hyun Lee, Hyeon-Seok Eom, Hyewon Lee, Do Young Kim, Sung-Nam Lim, Sung-Soo Yoon, Sung-Yong Kim, Ho Sup Lee
Korean J Intern Med. 2022;37(1):179-189. Published online December 14, 2021
Background/Aims: Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most fatal complications of hematopoietic cell transplantation (HCT), and defibrotide is the only curative drug. We conducted this study to confirm the survival rate of VOD/SOS patients diagnosed in Korea..
|
|
|
Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation
Taeyun Kim, Yunsuk Choi, Je-Hwan Lee, Silvia Park, Jae-Sook Ahn, Joon-Ho Moon, Ho-Jin Shin, Won Sik Lee, Dajung Kim, Ho Sup Lee
Korean J Intern Med. 2020;35(2):429-437. Published online January 10, 2019
Background/Aims: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in hematopoietic stem cell transplantation (HSCT) to reduce the incidence of graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in patients undergoing human leukocyte antigen (HLA)-mismatched allo..
|
|
|
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
Sang Kyun Sohn, Joon Ho Moon, In Hee Lee, Jae Sook Ahn, Hyeoung Joon Kim, Joo Seop Chung, Ho Jin Shin, Sung Woo Park, Won Sik Lee, Sang Min Lee, Hawk Kim, Ho Sup Lee, Yang Soo Kim, Yoon Young Cho, Sung Hwa Bae, Ji Hyun Lee, Sung Hyun Kim, Ik Chan Song, Ji Hyun Kwon, Yoo Jin Lee
Korean J Intern Med. 2018;33(6):1194-1202. Published online December 15, 2017
Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System.
Methods: A total of 279 H/VH risk MD..
|
|
|
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Ho Sup Lee, Chang-Ki Min
Korean J Intern Med. 2016;31(5):809-819. Published online September 1, 2016
Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalido..
|
|
|
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun
Korean J Intern Med. 2015;30(5):675-683. Published online August 27, 2015
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) ..
|
|
